tbuckley/cabot-search huggingface dataset:
Does it matter where you go for breast cancer surgery?
Authors: T. P. Hofer, S. T. Hawley, S. J. Katz
Journal: Journal of Clinical Oncology (2009)

6504 Background: Variation in receipt of local therapy for breast cancer has motivated research addressing whether treatment differences are attributable to surgeons. We assessed the amount of variation in receipt of mastectomy and breast reconstruction attributable to surgeons and evaluated patient and surgeon factors associated with treatment variability. Methods: Women with non-metastatic breast cancer aged 20–79 diagnosed from June 2005-February 2007 in Detroit and Los Angeles were surveyed after surgical treatment (response rate 72%, N = 2,260). Attending surgeons were surveyed (response rate 76.1%, N = 318). Patient and surgeon data were merged to SEER data (1764 patients and 295 surgeons). Two dependent variables were receipt of mastectomy and reconstruction. Patient variables were age, ethnicity, marital status, tumor size, behavior, and grade. Surgeon factors included age, gender, years in practice, percent of total practice devoted to breast cancer, hospital setting, and 3 scales measuring patient management processes. We used separate random effects models for each dependent variable to determine the amount of treatment variation attributable to surgeons and the amount of within-surgeon variability explained by patient and surgeon factors. Results: The number of patients per surgeon ranged from 1 to 35 (mean 5.5). One-third of women received mastectomy, 30% of whom received reconstruction. The amount of variation in mastectomy attributable to individual surgeons was moderate (8%, median odds ratio 1.7). Patient factors explained half this variation, while surgeon factors explained very little (&lt;1%). The amount of variation in reconstruction attributable to individual surgeons was large (18%, median odds ratio 2.3), with patient level factors explaining one third of this variation. One surgeon level factor (propensity to refer to a plastic surgeon prior to surgery) explained an additional third of the variance. Conclusions: These results suggest that individual surgeons and their attributes contribute only modestly to the variation in primary surgery for breast cancer. By contrast, individual surgeons play a much larger role in explaining the wide variation in receipt of breast reconstruction- primarily through preoperative referral to plastic surgeons. No significant financial relationships to disclose.
Letter to the editor: Need for a European network for enterovirus D68 surveillance after detections of EV-D68 of the new B3 lineage in Sweden and Italy, 2016
Authors: Elena Pariani, Laura Pellegrinelli, Alessandra Di Cesare Merlone, Antonio Piralla, Fausto Baldanti, Sandro Binda
Journal: Eurosurveillance (2017)
Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study
Authors: Shaji Kumar, Ian W Flinn, Stephen J. Noga, Parameswaran Hari, Robert M. Rifkin, Natalie Scott Callander, Manish Bhandari, Jeffrey Lee Wolf, Cristina Gasparetto, Amrita Krishnan, Daren D Grosman, Jonathan Glass, Entezam Asim Sahovic, Hongliang Shi, Iain J. Webb, Paul Richardson, S. Vincent Rajkumar
Journal: Blood (2008)
Safety and Efficacy of Von Willebrand Factor/Factor VIII Concentrate (Humate-P®) for Prophylaxis of Excessive Bleeding during Elective Surgery in Patients with von Willebrand Disease.
Authors: Jonathan Bernstein, Joan Cox Gill, Cindy A. Leissinger, Jorge Di Paola, Margaret V. Ragni, Rinah Shopnick, Leonard A. Valentino, Carl Friedman, Sigurd Knaub
Journal: Blood (2006)
Dysbiosis in Crohn's disease - Joint action of stochastic injuries and focal inflammation in the gut
Authors: Ludovica F. Buttó, Dirk Haller
Journal: Gut Microbes (2017)

Gut homeostasis involves interrelated biological networks that include the immune system, specialized cells of the epithelium, such as Paneth and goblet cells, as well as triggers derived from the microbiota. Disruption of these homeostatic interactions may lead to the pathogenesis of inflammatory bowel diseases (IBD). To develop more targeted and individual treatments in Crohn's disease and ulcerative colitis, it becomes more and more important to link key mechanisms of the disease pathogenesis to distinct IBD subsets. For the first time, our laboratory demonstrated a causal role of the microbiota for the development of Crohn's disease (CD)-like ileitis, supporting the hypothesis that a non-infectious, dysbiotic microbial ecosystem harbors aggressive traits relevant for the induction of chronic inflammation in the disease-susceptible host (i.e. TNFΔARE mouse model). Despite a growing body of evidence claiming a primary role for Paneth cells in the pathogenesis of ileal CD, we showed in the TNFΔARE mouse model that Paneth cell failure or exhaustion is a secondary event to inflammation. Therefore, additional mechanisms may act synergistically to initialize the development of CD-like pathology. Hereby, we propose a novel hypothesis suggesting that individual development of dysbiotic communities is based on stochastic injury and focal inflammation of the epithelial lining that propagate radially, finally leading to an aggressive microbial milieu.
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.
Authors: Marco Ladetto, Monica Astolfi, Loredana Santo, Ilaria Avonto, Federica Cavallo, Gloria Pagliano, Patrizia Pregno, Mariella Grasso, Anna Marina Liberati, Tommaso Caravita, Francesco Pisani, Tommasina Guglielmelli, Elisa Genuardi, Rossana Crivelli, Carmen Cristiano, Daniela Drandi, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2006)
Extracellular Domains of CD8a and β Subunits Are Required and Sufficient for HLA Class I Restricted Helper Activity of TCR-Engineered CD4+ T Cells.
Authors: Marleen M van Loenen, Renate S. Hagedoorn, Roelof Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Journal: Blood (2009)
Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.
Authors: Vi j ay Modur, Dean C Bottino, Susan Branford, Tillmann Krahnke, Fabrizio Pane, Marc Rudoltz, Yu Jin, Timothy P Hughes, Dong-Wook Kim, Jerald Radich, J. Carl Barrett
Journal: Blood (2008)
Abstract 192: High Fat Diet Promotes Haplotype Dependent Differential Transcriptional Regulation of the Human Angiotensinogen Gene
Authors: Anita Rana, Nitin Puri, Sudhir Jain, Ashok Kumar
Journal: Circulation Research (2015)

Angiotensinogen (AGT) is the only known precursor to angiotensin II. Systemic renin angiotensin aldosterone system (RAAS) is activated in human and experimental models of obesity. RAAS activation in obesity is linked to the development of cardiovascular pathophysiologies. We have identified polymorphisms in 2.5 Kb promoter of human angiotensinogen gene (hAGT) that forms two haplotype (Hap) blocks: -6A/G (-1670A/G, -1562C/T, -1561T/C) and -217A/G (-532T/C, -793A/G, -1074T/C,&amp; -1178G/A). Hap -6A/-217A (Hap -6A) is associated with human hypertension whereas, Hap -6G/-217G (Hap -6G) reduces cardiovascular risk. Here, we examine high fat diet-mediated allele-specific transcriptional regulation of the hAGT gene in adipose tissue, in vivo, in transgenic (TG) mice engineered with either haplotype of the hAGT gene. Twelve-week-old male TG mice with Hap –6A or –6G were fed normal diet (10% kcal as fat) and high fat diet (60% kcal as fat) for 10 weeks. Using Q - RT PCR and western blot we show increased hAGT expression in adipose tissue of the Hap -6A-TG mice after high fat diet than control diet (Hap -6A-0.68±0.04 vs. Hap -6G- 0.33±0.03 A.U., p&lt;0.05). ChIP assay shows greater chromatin binding of GR, MR, CEBPβ and STAT3 transcriptional factors (Hap -6A- 0.80±0.04 vs. Hap -6G- 0.26±0.06 A.U., p&lt;0.05) to the hAGT transgenes in Hap -6A TG mice after high fat diet. No significant change was observed in the endogenous mouse AGT gene. In addition, after high fat diet, change ([[Unable to Display Character: &amp;#8710;]]) in inflammatory and redox markers was significantly (p&lt;0.05) greater in TG mice with Hap I including, IL1 (4.6±0.8 vs. 2.1±0.49 fold), IL6 (4.0±0.69 vs. 2.1±0.2 fold) and NOX1 (8.3±0.4 vs. 2.5±0.6 fold). This is accompanied by reduction in levels of antioxidant defenses (SOD1: 0.97±0.0 vs. 1.4±0.1 fold; HO1: 0.77±0.1 vs. 1.3±0.2 fold) &amp; activation of MAPK14 and ERK1/2 signaling. Taken together, our results show that SNPs in the hAGT Hap -6A favor high fat diet induced binding of transcriptional factors GR, MR, CEBP-β and STAT3 that lead to elevated expression of the hAGT in expanded mass of the adipose tissue. This also activates the RAAS with pathophysiological implications including, phosphorylation of kinases such as MAPK14 and ERK2, increase in tissue pro-inflammatory and oxidative stress molecules.
Ex Vivo Expansion of Hematopoietic Progenitors from CD34+-Selected Cells on Mouse Embryonic Fibroblast Feeders in a Non-Contact Co-Culture Using Matrigel or Fibronectin-Coated Inserts.
Authors: Astrid Voigt, Angelika Müller, Ralf Häfer, Felix Zintl
Journal: Blood (2004)
Effective Treatment with Imatinib Mesylate and Donor Lymphocyte Infusion Following Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Authors: Jianyong Li, Hanxin Wu, Sixuan Qian, Ming Hong, Bing Xiao, Run Zhang, Changgeng Ruan
Journal: Blood (2005)
Rituximab Plus CHOP Followed by Maintenance Rituximab as Initial Therapy for Advanced Stage Indolent Non-Hodgkin’s Lymphoma (NHL); Initial Results of Induction Therapy in a Phase II Study.
Authors: Jane E. Huang, Lowell Hart, Jonathon Polikoff, Virginia Langmuir, Fan Zhang, Louis Fehrenbacher
Journal: Blood (2004)
Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.
Authors: Shaji K. Kumar, Amrita Krishnan, Vivek Roy, Todd M Zimmerman, Morie Abraham A Gertz, Keith E. Stockerl-Goldstein, Francis K Buadi, Cara Rosenbaum, Ann Birgin, Mark Fiala, Valeria Jiminez, Michele Maharaj, Michael N. Needle, Ravi Vij
Journal: Blood (2012)
Revisiting the IGF-1R Signaling Pathway in Myeloproliferative Neoplasms: Quantification of IGF-1 Receptor May be Useful in the Differential Diagnosis of Polycythemia
Authors: Guanfang Shi, Stacey Baptiste, Maryna Yarotska, Hemant Sindhu, Ching Wong, Madhumati Kalavar, Vladimir Gotlieb, Jen-Chin Wang
Journal: Blood (2014)
Essential Roles of C/EBPβ in Survival of Ly6C– monocytes
Authors: Akihiro Tamura, Hideyo Hirai, Asumi Yokota, Atsushi Sato, Hisayuki Yao, Masaki Iwasa, Aya Fujishiro, Yasuo Miura, Taira Maekawa
Journal: Blood (2014)
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group
Authors: GJ Ossenkoppele, B van der Holt, GEG Verhoef, SMGJ Daenen, LF Verdonck, P Sonneveld, PW Wijermans, J van der Lelie, WLJ van Putten, B Löwenberg
Journal: Leukemia (1999)
Immunological Prophile of FA. A Multicentric retrospective Analysis of 61 Patients
Authors: Paola Terranova, Enrico Cappelli, Regis Peffault De Latour, Johanna Svahn, Jean Soulier, Robbert Bredius, Marleen Kok, Els Jol van der Zijde, Marteen van Tol, Gérard Socié, Helene Moins, Carlo Dufour, Elisabeth T Korthof
Journal: Blood (2011)
IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor
Authors: Rahul Nahar, Parham Ramezani-Rad, Cihangir Duy, Sinisa Dovat, B. Hilda Ye, Ari M. Melnick, Markus Muschen
Journal: Blood (2010)
Acid Angiotensinase, Renin, and Acid Adenosine Triphosphatase in Rat Kidney Lysosomes
Authors: Masao Matsunaga, Jun Kira, Noboru Saito, Koichi Ogino, Masao Takayasu
Journal: Circulation (1968)

1. Kidney angiotensinases are located in two kinds of subcellular fraction-lysosomal and microsomal. Lysosomal angiotensinase is active at an acid pH and inhibited by DFP, suggesting a relationship to plasma acid angiotensinase. Most of the activity was released from the particles by freezing and thawing. The microsomal enzyme is active near neutral pH, activated by calcium ion and inhibited by EDTA . 2. About 70 per cent of renin activity was released from the subcellular particles in lysosomal fraction of rat kidney by freeze-thaw method. It revealed only one peak on either Sephadex G-100 gel filtration or DEAE-cellulose column chromatography. The molecular weight of renin was calculated as 40, 000-50, 000. 3. At least three components of acid ATPase were found in lysosomal fraction of rat kidney by DEAE-cellulose column chromatography.
Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011)
Authors: Cathy J. Bradley, K. Robin Yabroff, Angela B. Mariotto, Christopher Zeruto, Quyen Tran, Joan L. Warren
Journal: Journal of Clinical Oncology (2017)

Purpose Multiple agents for advanced non–small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about their use and associated spending and survival. Methods We used SEER-Medicare data for elderly patients with a new diagnosis of advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163). We estimated the adjusted percentage of patients who received each agent, days while on treatment, survival, and spending in the 12 months after diagnosis. Results During the 12-year study period, a marked shift in treatment occurred along with a rapid adoption of pemetrexed (39.2%), erlotinib (20.3%), and bevacizumab (18.9%) and a decline in paclitaxel (38.7%), gemcitabine (17.0%), and vinorelbine (5.7%; all P &lt; .05). The average total days on therapy increased by 5 days (from 103 to 108 days). Patients who received bevacizumab, erlotinib, or pemetrexed had the longest treatment durations on average (approximately 146 days v 75 days for those who did not receive these agents). Approximately 44% of patients received antineoplastic agents in the last 30 days of life throughout the study period. Acute inpatient spending declined (from $29,376 to $23,731), whereas outpatient spending increased 23% (from $37,931 to $46,642). Median survival gains of 1.5 months were observed. Conclusion Considerable shifts in the treatment of advanced-stage NSCLC occurred along with modest gains in survival and total Medicare spending. More precise outcome information is needed to inform value-based treatment decisions for advanced-stage NSCLC.
Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia.
Authors: Shao-qing Kuang, Weigang Tong, Hui Yang, Mathew K. Lee, Zhi-Hong Fang, Jeroslav Jelinek, Jean-Pierre Issa, Guillermo Garcia-Manero
Journal: Blood (2007)
Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation
Authors: Carlo Pappone, Salvatore Rosanio, Giuseppe Augello, Giuseppe Gallus, Gabriele Vicedomini, Patrizio Mazzone, Simone Gulletta, Filippo Gugliotta, Alessia Pappone, Vincenzo Santinelli, Valter Tortoriello, Simone Sala, Alberto Zangrillo, Giuseppe Crescenzi, Stefano Benussi, Ottavio Alfieri
Journal: Journal of the American College of Cardiology (2003)
Long-term results of catheter ablation for idiopathic ventricular tachycardia originated from the right ventricular outflow.
Authors: Junko Mukai, Hiroshi Nakagawa, Kenji Nagata, Shinji Karakawa, Wataru Shimizu, Yukiko Tsuchioka, Mitsunori Okamoto, Hideo Matsuura, Goro Kajiyama
Journal: Circulation (1993)

We performed catheter ablation in 10 consecutive patients with idiopathic monomorphic right ventricular tachycardia and studied the long-term outcome. All ventricular tachycardias had a left bundle branch block configuration with an inferior axis, and originated from right ventricular outflow. Antiarrhythmic drugs (3-6 drugs) had been ineffective in controlling ventricular tachycardia. The 2 patients who underwent direct-current ablation (2 shocks of 150 J) had no recurrence of ventricular tachycardia and did not require antiarrhythmic drugs during a follow-up of 56 and 51 months, respectively. Of the 8 patients who underwent radiofrequency ablation (30-40 watt, 20-40 sec, 2-15 application, using Inter Nova RA 50, 13.56 MHz), 1 patient had no recurrence of ventricular tachycardias and did not require antiarrhythmic drugs, 4 patients had no recurrence of ventricular tachycardias but did require anti-arrhythmic drugs, and 3 patients experienced recurrence of non-sustained ventricular tachycardia despite the use of antiarrhythmic drugs during a follow-up of 15-40 months. There were no complications except for cardiac perforation which occurred immediately after direct-current ablation in 1 patient. In conclusion, long-term success in preventing ventricular tachycardia was achievable with direct-current ablation, but this success was associated with serious risks, such as cardiac perforation. Radiofrequency ablation was safer than direct-current ablation, but had a lower long-term success rate.
Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or <i>BRCA1/2</i> mutation-associated breast cancer.
Authors: Melinda L. Telli, Kirsten Timms, Julia E. Reid, Christopher Neff, Victor Abkevich, Alexander Gutin, Zaina Sangale, Diana Illiev, Joshua Timothy Jones, Bryan Hennessy, Jerry S. Lanchbury, Gordon B. Mills, Anne-Renee Hartman, James M. Ford
Journal: Journal of Clinical Oncology (2015)

1018 Background: The HRD-LOH (loss of heterozygosity) score is significantly associated with favorable response to neoadjuvant platinum-based therapy in PrECOG 0105. We set out here to assess the combined HRD score, an unweighted sum of LOH, telomeric allelic imbalance (TAI) and large-scale state transitions (LST) scores. In combination, these measures are a more robust predictor of HR deficiency than the individual components. Methods: The HRD threshold was previously established by analyzing scores in a training cohort of 497 breast and 561 ovarian chemotherapy naive tumors with known defects in HR, and defining a cut-off with 95% sensitivity to detect those HR deficient tumors. This threshold, along with BRCA1/2 tumor mutation data, was used to predefine tumors from the PrECOG 0105 cohort (N = 93; 72 with molecular data) as either HR deficient (HRD score ≥ the threshold OR a tumor BRCA1/2 mutation) or HR non-deficient (HRD score < the threshold and no tumor BRCA1/2 mutation). Results: In univariate analysis, a HRD score ≥ 42 was significantly associated with both RCB 0/1 and pCR (p = 0.0086; p = 0.010). In addition, HR deficiency was significantly associated with both RCB 0/1 and pCR (OR = 5.00 [1.65, 15.2], p = 0.0029; OR = 6.65 [1.40, 31.6], p = 0.0050), and identified responders lacking a deleterious BRCA1/2 mutation. When the analysis was confined to tumors with intact BRCA1/2, HR deficiency was no longer significantly associated with RCB 0/1 or pCR; however power to detect this association was limited. HR deficiency remained a significant predictor of RCB 0/1 when the score was adjusted by clinical variables including grade, stage, cycles of chemotherapy, and age at diagnosis (p = 0.0075). Conclusions: In this study, HRD status provides significant improvement over clinical variables, or BRCA1/2 status, in identifying tumors with an increased likelihood of response to platinum-based neoadjuvant therapy among patients with TNBC. Clinical use of the HRD test has the potential to identify TNBC patients likely to respond beyond those currently identified by germline BRCA1/2 mutation screening. Prospective evaluation is warranted. Clinical trial information: NCT00540358.
Inhibition Of Inflammation Driven Leukemia Stem Cell Self-Renewal With a Selective JAK2 Antagonist
Authors: Angela C Court Recart, Anil Sadarangani, Elizabeth Chun, Cayla N Mason, Qingfei Jiang, Christian L Barrett, Russell Wall, Daniel J Goff, Ifat Geron, Alice Shih, Heather S. Leu, Wenxue Ma, Mark D. Minden, Kelly A Frazer, Marco A. Marra, Leslie A Crews, Catriona HM Jamieson
Journal: Blood (2013)
Growth Differentiation Factor 15 Plasma Level in patients with Multiple Myeloma: A Study of Intergroupe Francophone Du Myelome
Authors: Jill Corre, Murielle Roussel, Anne Huynh, Melanie Gadelorge, Elodie Labat, Patrick Laharrague, Philippe Moreau, Thierry Facon, Hervé Avet-Loiseau, Jean-Jacques Fournié, Michel Attal, Philippe Bourin
Journal: Blood (2008)
First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis
Authors: Erica K. Evans, Brian L. Hodous, Alexandra Gardino, Julia Zhu, Adam Shutes, Alison Davis, Joseph Kim, Kevin Wilson, Doug Wilson, Yulian Zhang, Nancy E. Kohl, Timothy Guzi, Christoph Lengauer
Journal: Blood (2014)
Myeloproliferative Neoplasm Patient Symptom Burden and Quality of Life: Evidence of Significant Impairment Compared to Controls Using Multivariate Analysis
Authors: Lesley A. Anderson, Glen J. Titmarsh, Amylou C. Dueck, Andrew Duncombe, Ruben A. Mesa, Robyn M. Scherber, Heidi E. Kosiorek, Frank de Vocht, Mike Clarke, Mary Frances McMullin
Journal: Blood (2015)
Role of the Urokinase Receptor (uPAR) in the Cross-Talk of Hematopoietic Stem Cells with the Bone Marrow Microenvironment
Authors: Nunzia Montuori, Patrizia Ricci, Bianca Serio, Valeria Visconte, Claudio La Penna, Ada Pesapane, Antonio M. Risitano, Bruno Rotoli, Guido Rossi, Pia Ragno, Carmine Selleri
Journal: Blood (2008)
Outcomes of Pregnancies for Women with Severe Chronic Neutropenia with or without G-CSF Treatment.
Authors: Laurence A. Boxer, Audrey Anna Bolyard, Tracy M. Marrero, Blanche P Alter, Mary Ann Bonilla, Dan Link, Peter E. Newburger, Philip S. Rosenberg, Akiko Shimamura, David C. Dale
Journal: Blood (2010)
A Missed Opportunity to Discuss Racial and Gender Bias in Dermatology—Reply
Authors: Stephen Symes, Joshua D. Fox, Robert S. Kirsner
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
The Prognostic Role of Interim PET after First Chemotherapy Cycle and PET Sequential Evaluation of Response to ABVD in Hodgkin Lymphoma Patients - the Polish Lymphoma Research Group (PLRG) Observational Study
Authors: Jan M Zaucha, Bogdan Malkowski, Edyta Subocz, Stephane Chauvie, Joanna Tajer, Waldemar Kulikowski, Agnieszka Fijolek-Warszewska, Alberto Biggi, Federico Fallanca, Malgorzata Kobylecka, Miroslaw Dziuk, Dariusz Woszczyk, Justyna Rybka, Renata Kroll-Balcerzak, Fabrizio Bergesio, Agnieszka Romanowicz, Agnieszka Chamier-Cieminska, Pawel Kurczab, Agnieszka Giza, Krzysztof Lesniewski-Kmak, Wanda Knopinska-Posluszny, Jan Walewski, Andrea Gallamini
Journal: Blood (2015)